Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Aug;34(8):771-83.
doi: 10.1007/s11745-999-0423-3.

Olestra formulation and the gastrointestinal tract

Affiliations
Review

Olestra formulation and the gastrointestinal tract

R J Jandacek et al. Lipids. 1999 Aug.

Abstract

Olestra is a mixture of compounds comprising sucrose esterified with 6-8 long-chain fatty acids. It is not hydrolyzed by pancreatic lipase and as a result is not absorbed from the small intestine. Olestra in general has physical properties similar to those of a triacylglycerol with the same fatty acid composition. Foods made with olestra are virtually identical in taste and texture to those made with typical triacylglycerols. Olestra consumption does not generate hydrolytic products in the small intestine and, therefore, does not generate some of the signals that alter motility in the gastrointestinal tract. A reduction in gastroesophageal reflux with olestra, in contrast to triacylglycerols, is consistent with a lack of effect on stomach emptying. Unlike triacylglycerols that are absorbed in the proximal small intestine, olestra is distributed throughout the small intestine during transit and passes into the colon. In the colon, olestra's effects depend on its physical properties. Liquid nondigestible lipids result in separation of oil from the fecal matrix. Olestra formulations made with specific fatty acid compositions, particularly those containing a solid sucrose polyester component including behenic acid, possess appropriate rheology to hinder separation of oil from the rest of the fecal matrix, thereby reducing gastrointestinal symptoms.

PubMed Disclaimer

References

    1. Am J Clin Nutr. 1976 Nov;29(11):1204-15 - PubMed
    1. Am J Physiol. 1973 Sep;225(3):574-85 - PubMed
    1. J Nutr. 1980 Oct;110(10):1992-9 - PubMed
    1. J Nutr. 1972 Sep;102(9):1177-80 - PubMed
    1. Regul Toxicol Pharmacol. 1997 Oct;26(2):200-9 - PubMed

LinkOut - more resources